Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy
Eur J Heart Fail
.
2026 May 10:xuag141.
doi: 10.1093/ejhf/xuag141.
Online ahead of print.
Authors
Hubert B Haywood
1
,
Uchechukwu Ikeaba
2
,
Gregg C Fonarow
3
,
Haolin Xu
2
,
Senthil Selvaraj
1
,
Sabra C Lewsey
4
,
Brooke Alhanti
2
,
James J McDermott
5
,
Jason Wright
5
,
Muthiah Vaduganathan
6
,
Stephen J Greene
1
2
Affiliations
1
Division of Cardiology, Duke University School of Medicine, 2301 Erwin Road, Durham, NC 27705, USA.
2
Duke Clinical Research Institute, 300 West Morgan Street, Durham, NC 27701, USA.
3
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
4
Division of Cardiovascular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
6
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
PMID:
42107000
DOI:
10.1093/ejhf/xuag141
No abstract available
Keywords:
ATTR-CM; Amyloid; Clinic; Heart failure; Outpatient.
Grants and funding
American Heart Association
AstraZeneca